Kennedy Capital Management LLC Raises Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kennedy Capital Management LLC increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 26.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,426 shares of the medical equipment provider's stock after acquiring an additional 6,505 shares during the period. Kennedy Capital Management LLC's holdings in Zimmer Biomet were worth $3,320,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at $25,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at about $39,000. OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth $40,000. SRS Capital Advisors Inc. lifted its position in shares of Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock valued at $51,000 after acquiring an additional 285 shares in the last quarter. Finally, Atala Financial Inc bought a new position in Zimmer Biomet in the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

NYSE:ZBH traded up $0.96 during mid-day trading on Friday, hitting $97.90. The company's stock had a trading volume of 4,367,870 shares, compared to its average volume of 1,650,696. The stock has a market cap of $19.37 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 1 year low of $96.58 and a 1 year high of $123.96. The business's fifty day moving average is $105.95 and its two-hundred day moving average is $106.78. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the business earned $2.20 earnings per share. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.98%. Zimmer Biomet's payout ratio is currently 21.57%.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.95% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZBH. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. JMP Securities reaffirmed a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays dropped their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Finally, BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research note on Monday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.